Approval

FDA approves Bayer's asundexian, the first factor XIa inhibitor, to prevent repeat stroke

Sunharbo 50 mg, taken with antiplatelet therapy, is now approved for adults who recently had a non-cardioembolic ischemic stroke or a high-risk TIA. In the Phase 3 OCEANIC-STROKE trial, adding it cut ischemic stroke by 26% compared with antiplatelets alone, and major bleeding rates were reported as similar. China also approved the drug recently.

Written by Gosset from public sources. Source types: Press release · News article. Sources are available to Gosset users. Log in to see them.

Schematic animation of clotting proteins in a blood vessel, factor XI switched on to factor XIa and feeding clot growth, and the small molecule asundexian binding factor XIa's active centre while a separate bleeding-control pathway keeps running.
Asundexian: blocking factor XIa in the clotting chain. Watch the mechanism animation on the asundexian page.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call